SCHEMBL6922912

SCHEMBL6922912

O=c1c2ccc(-c3ccccn3)cc2nc2n1CCC(F)CC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
TDP1 Q9NUW8 2/20 0.46
NSD2 O96028 1/20 0.44
ALDH1A1 P00352 6/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
KDM4E B2RXH2 2/20 0.43
USP2 O75604 1/20 0.43
CYP1A2 P05177 1/20 0.43
BCHE P06276 1/20 0.43
CFTR P13569 1/20 0.43
ALOX15 P16050 1/20 0.43
ACHE P22303 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GOPC Q9HD26 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059551 0.92 NPC1 (0.41) NPC1RAB9ATDP1NSD2ALDH1A1
SCHEMBL6922313 0.91 NPC1 (0.45) NPC1RAB9ATDP1NSD2ALDH1A1
SCHEMBL6922375 0.89 NPC1 (0.48) NPC1RAB9ATDP1NSD2ALDH1A1
SCHEMBL6922412 0.88 NPC1 (0.45) NPC1RAB9ATDP1NSD2ALDH1A1
SCHEMBL6920613 0.88 NPC1 (0.43) NPC1RAB9ATDP1NSD2ALDH1A1
SCHEMBL14239320 0.86 NPC1 (0.41) NPC1RAB9ATDP1NSD2ALDH1A1
SCHEMBL14238884 0.86 NPC1 (0.43) NPC1RAB9ATDP1NSD2ALDH1A1
SCHEMBL12059134 0.86 NPC1 (0.43) NPC1RAB9ATDP1NSD2ALDH1A1
SCHEMBL6922198 0.85 ALDH1A1 (0.60) NPC1RAB9ATDP1NSD2ALDH1A1
SCHEMBL12059540 0.85 NPC1 (0.47) NPC1RAB9ATDP1NSD2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012170845-A2 METABOTROPIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF HEFFERNAN MICHELE L R (US) 2012-12-13 WO disclosed
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 NPC1 811/4885RAB9A 1387/4885TDP1 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.